A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study

Gordon Cook(University of Leeds), Graham Jackson(Newcastle College), Faith E. Davies(NYU Langone Health), David A. Cairns(BMW (Germany)), Sarah Brown(University of Leeds), Charlotte Pawlyn(Royal Marsden NHS Foundation Trust), Martin Kaiser(Royal Marsden NHS Foundation Trust), Anna Hockaday(University of Leeds), Gareth J. Morgan(Hywel Dda University Health Board), Vallari Shah(Bridge Pharma (United States)), Walter M. Gregory(University of Leeds), J. Anthony Child(University of Leeds), Kara‐Louise Royle(University of Leeds)
The Lancet Haematology
February 10, 2019
10.1016/s2352-3026(18)30220-5
Cited by 109

Related Papers

The Global Syndemic of Obesity, Undernutrition, and Climate Change: The Lancet Commission report
|The Lancet|2019|3.1k
Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936
|Leukemia|2003|3k
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k